Belite Bio (NASDAQ:BLTE) CEO Sells $65,827.75 in Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CEO Yu-Hsin Lin sold 365 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total transaction of $65,827.75. Following the sale, the chief executive officer owned 170,569 shares in the company, valued at approximately $30,762,119.15. The trade was a 0.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Belite Bio Stock Performance

BLTE opened at $162.80 on Monday. The stock has a market capitalization of $6.53 billion, a P/E ratio of -59.63 and a beta of -1.22. Belite Bio, Inc. Sponsored ADR has a 12 month low of $60.00 and a 12 month high of $200.00. The firm’s fifty day simple moving average is $152.50 and its 200 day simple moving average is $159.85.

Belite Bio (NASDAQ:BLTE) last released its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Belite Bio, Inc. Sponsored ADR will post -3.17 EPS for the current fiscal year.

Key Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
• Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
• Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
• Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BLTE. Zacks Research upgraded Belite Bio from a “hold” rating to a “strong-buy” rating in a report on Monday, July 20th. Truist Financial set a $217.00 target price on Belite Bio in a research note on Friday, May 22nd. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research report on Friday. HC Wainwright upped their price target on Belite Bio from $200.00 to $214.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Mizuho set a $220.00 price target on shares of Belite Bio in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $205.80.

Hedge Funds Weigh In On Belite Bio

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its holdings in shares of Belite Bio by 28,200.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock valued at $45,000 after acquiring an additional 282 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Belite Bio during the fourth quarter worth about $103,000. Persistent Asset Partners Ltd bought a new stake in Belite Bio during the fourth quarter worth about $108,000. Bank of America Corp DE boosted its position in Belite Bio by 28.1% during the third quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after purchasing an additional 257 shares during the last quarter. Finally, Independent Advisor Alliance acquired a new position in Belite Bio during the fourth quarter valued at approximately $211,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.